title: Immunotherapeutic approaches to ovarian cancer treatment.
abstract: Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.
authors: Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA USA.
authors: Cariad
authors: C
authors: Chester
authors: Stanford Women's Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305 U.S.A.
authors: Oliver
authors: O
authors: Dorigo
authors: Stanford Women's Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305 U.S.A.
authors: Jonathan S
authors: JS
authors: Berek
authors: Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA USA.
authors: Holbrook
authors: H
authors: Kohrt
keywords: ACT; Antibody; Cancer vaccine; ID8; IDO; Immune checkpoint blockade; Ovarian cancer; TAM